Lipid Nanoparticles Deliver Dual-Action mRNA and Drug Therapy Against Oral Cancer
Key Insights
Penn researchers developed a lipid nanoparticle platform that co-delivers p53 mRNA (search) and the antifungal drug ciclopirox to treat oral squamous cell carcinoma (search), published in Advanced Materials.
The dual therapy simultaneously kills cancer cells and reprograms the tumor microenvironment to be less immunosuppressive, showing reduced tumor burden and extended survival in preclinical models.
More than 70% of OSCC cases involve p53 mutations, and the five-year survival rate remains approximately 50% with standard treatments often causing permanent functional impairment.
A multidisciplinary team at the University of Pennsylvania has engineered a lipid nanoparticle (LNP) platform that delivers a combination of cancer-fighting therapies directly to oral squamous cell carcinoma (search) (OSCC), the most common form of head and neck cancer. The findings, published in Advanced Materials, demonstrate that co-delivering messenger RNA encoding the tumor-suppressor protein p53 alongside ciclopirox—an FDA-approved antifungal drug with anticancer and immune-modulating activity—can reduce tumor growth and extend survival in preclinical models, including those resistant to p53-based therapy.
The work addresses a pressing clinical need. OSCC carries a five-year survival rate of approximately 50%, and new cases are projected to rise by roughly 30% over the next decade. Standard treatments such as ablative surgery and radiation often leave patients with permanent disfigurement or profound, lifelong impairment of essential oral functions including speaking and swallowing.
A two-pronged therapeutic strategy
More than 70% of OSCC cases involve mutations in the TP53 gene, which normally produces p53—a protein that detects cellular damage and either halts cell division or initiates programmed cell death. When p53 is disabled, abnormal cells can continue multiplying unchecked. Delivering p53 mRNA (search) offers a way to instruct tumor cells to produce functional p53 temporarily, without permanently altering their DNA.
"mRNA lipid nanoparticles are a potentially promising technology to treat oral cancer, since tumors are accessible locally and can also be leveraged to generate a systemic immune response that targets metastatic tumors," said Michael Mitchell, the Hibbert Professor of Bioengineering at Penn Engineering and Lipid Nanoparticle Delivery Systems Group Leader at the Penn Institute for RNA Innovation. "However, tumor cells can be difficult to target and deliver mRNA into, so we designed a novel LNP delivery system for delivery into oral cancer cells."
The second component, ciclopirox, contributes direct chemotherapeutic effects while also influencing the immune environment surrounding the tumor. Together, the two therapies act simultaneously through multiple mechanisms—directly killing cancer cells while reprogramming the immune system to target them rather than protect them.
"The potential shift is from one-size-fits-all monotherapy toward a single, tunable delivery vehicle that works even when one of its two drugs fails, which matters because oral tumors vary enormously from patient to patient," said first author Marshall Padilla, a former postdoctoral fellow in the Department of Bioengineering and the Center for Innovation & Precision Dentistry (CiPD), now an assistant professor at Stanford University.
Reprogramming the tumor microenvironment
The researchers found that both p53 and ciclopirox possess innate chemotherapeutic properties and can create a less immunosuppressive tumor microenvironment. Among the cells affected may be tumor-associated macrophages—immune cells that can either help eliminate cancer or, under the influence of a tumor, support its growth and shield it from immune destruction.
"In aggressive, p53-therapy-resistant cancer models, this new LNP platform significantly reduces tumor burden and extends survival," said Anh D. Le, the Norman Vine Endowed Professor of Oral Rehabilitation and chair of the Department of Oral & Maxillofacial Surgery / Pharmacology at Penn Dental Medicine.
The study suggests that the combined treatment may reprogram these macrophages, shifting them away from a tumor-protective state. However, the researchers emphasize that the precise mechanism remains unresolved. "The mechanism of how ciclopirox and p53 reprogram tumor-associated macrophages isn't fully worked out," Padilla noted. "The paper points to a plausible pathway but flags that it needs to be confirmed."
Advantages of local delivery with systemic potential
Because many oral cancers can be reached locally, an LNP-based therapy could potentially be administered in a way that concentrates treatment near the tumor while limiting exposure to healthy tissues. At the same time, local treatment could stimulate a broader immune response capable of recognizing malignant cells elsewhere in the body—a prospect particularly significant for OSCC, which can recur or spread to regional lymph nodes and distant sites.
The versatility of the platform means it could benefit far more patients than traditional single-agent therapies, Le said, "opening the door to a broader, more effective class of treatments."
Future directions and remaining questions
The team plans to refine the nanoparticle design for greater precision, expand the therapeutic payloads beyond p53 and ciclopirox, and explore alternative routes of administration. Future studies will also test the platform in more complex preclinical models that better reflect the genetic diversity of real patient tumors—variability that has historically undermined p53 therapies, according to Padilla.
"This work opens the door to an entirely new class of customizable nanotherapies for oral cancer," said Le. "This breakthrough was only possible because Penn's deeply collaborative culture brings engineers, clinicians, and scientists into the same space—often tackling the same unmet clinical need—creating the kind of cross-disciplinary momentum that enables advances like this."
The current work remains preclinical and does not establish that the therapy is safe or effective in people. Substantial questions about dosing, biodistribution, immune effects, manufacturing, and safety must still be answered before clinical testing can begin.